

B1
2. (Twice Amended) [A method of treatment of] The method of claim 1, wherein said solid tumor is a metastatic [neoplastic disease in a human in need of such treatment, which comprises administering a therapeutically effective amount of one or more arsenic compounds to said human] tumor.

B2
9. (Twice Amended) The method of claim 4 wherein said tumor is a tumor of the central nervous system selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma and oligodendroglioma.

B3
14. (Twice Amended) The method of claim 1, in which said other therapeutic agent is a chemotherapeutic agent or radiotherapeutic agent.

15. (Twice Amended) The method of claims 1 or 2, in which said administration is made parenterally, topically, dermally, directly into the tumor or orally.

16. (Twice Amended) The method of claim 1, in which said other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26 (vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, and therapeutic vaccines.

17. (Twice Amended) The method of claim 1 or 2, in which said administration is made via an implantation device.